학술논문
Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care?
Document Type
Editorial & Opinion
Author
Ballantyne CM; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: cmb@bcm.edu.; Varughese MG; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: https://twitter.com/MVarugheseMD.; Abushamat LA; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: https://twitter.com/LaylaAbushamat.
Source
Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print Cited Medium: Internet ISSN: 1558-3597 (Electronic) Linking ISSN: 07351097 NLM ISO Abbreviation: J Am Coll Cardiol Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Funding Support and Author Disclosures Dr Ballantyne has received grant/research support through his institution from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, Novartis, and Regeneron; is a consultant for Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Esperion, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Pfizer, Regeneron, and Roche Diagnostic; and has received consulting fees from 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, and Roche Diagnostic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.